CIK 0001501697 · Non-accelerated filer<br>Smaller reporting company
X4 Pharmaceuticals, Inc
Sign in to watch- Ticker
- XFOR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273181608
- Phone
- 857-529-8300
- Business address
- 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
- Former names
- Arsanis, Inc.
- Open-market buys, last 90 days
- $11,884
- in 1 filing
- Open-market sales, last 90 days
- $33,658
- in 1 filing
Net −$21,775. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-01 | KIRSKE DAVID Chief Financial Officer | Sale | −11,767 | $2.86 | $34K | 155,983 |
| 2026-06-30 | KIRSKE DAVID Chief Financial Officer | Sale | −8,543 | $4.26 | $36K | 167,750 |
| 2026-05-12 | KIRSKE DAVID Chief Financial Officer | Sale | −16,961 | $4.29 | $73K | 176,293 |
| 2025-10-29 | KIRSKE DAVID Chief Financial Officer | Grant or award · Stock Option (right to buy) | +1,552,769 | 1,552,769 | ||
| 2025-08-14 | KIRSKE DAVID Chief Financial Officer | Grant or award | +193,254 | 193,254 | ||
| 2025-08-14 | KIRSKE DAVID Chief Financial Officer | Grant or award · Stock Option (right to buy) | +352,800 | 352,800 | ||
| 2025-08-12 | KIRSKE DAVID Chief Financial Officer | Grant or award · Stock Option (right to buy) | +1,073,249 | 1,073,249 |
Page 1 of 1 · 7 trades